Double-Drug attack aims to wipe out lingering leukemia
NCT ID NCT06284486
Summary
This study is testing whether two oral medications, venetoclax and revumenib, can work together to eliminate minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) who are in remission. MRD refers to a small number of cancer cells that remain after treatment and can cause the disease to return. The trial aims to find a safe dose and see if this combination can clear these hidden cells to help keep the cancer from coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21218, United States
Contact Email: •••••@•••••
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.